TG Therapeutics
TGTX
125 hedge funds and large institutions have $548M invested in TG Therapeutics in 2018 Q1 according to their latest regulatory filings, with 31 funds opening new positions, 38 increasing their positions, 33 reducing their positions, and 14 closing their positions.
121% more first-time investments, than exits
New positions opened: 31 | Existing positions closed: 14
87% more capital invested
Capital invested by funds: $293M → $548M (+$255M)
67% more call options, than puts
Call options by funds: $17.4M | Put options by funds: $10.4M
15% more repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 33
15% more funds holding
Funds holding: 109 → 125 (+16)
0.43% more ownership
Funds ownership: 50.63% → 51.07% (+0.43%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$31.6M |
| 2 |
ACA
Avoro Capital Advisors
New York
|
+$24.7M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
+$7.72M |
| 4 |
HCMT
Highland Capital Management (Texas)
Dallas,
Texas
|
+$5.93M |
| 5 |
Millennium Management
New York
|
+$4.98M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BM
Bridger Management
New York
|
-$25.8M |
| 2 |
SAM
Senzar Asset Management
New York
|
-$11.2M |
| 3 |
KCM
Kennedy Capital Management
St Louis,
Missouri
|
-$4.8M |
| 4 |
State Street
Boston,
Massachusetts
|
-$3.75M |
| 5 |
JP Morgan Chase
New York
|
-$3.31M |
TGTX Hedge Fund Activity: Q1 2018 in Review
125 of the 4,373 institutional investors tracked by Wall St. Rank reported a position in TG Therapeutics (TGTX) for Q1 2018, worth a combined $548M — up 87% from $293M a quarter earlier.
Buyers outnumbered sellers: 31 funds opened new TGTX positions and 14 closed out — a net gain of 17 holders — while 38 added to existing stakes and 33 trimmed.
The largest buyer was RA Capital Management, opening a new position worth an estimated $31.6M. The largest seller was Bridger Management, cutting an estimated $25.8M.
- 125 institutional investors held TG Therapeutics (TGTX) as of Q1 2018, up from 109 in Q4 2017.
- Funds reported $548M of TG Therapeutics stock for Q1 2018, up 87% quarter-over-quarter.
- 31 funds opened new TG Therapeutics positions in Q1 2018 and 14 closed out, a net change of +17 holders.
- The largest TG Therapeutics buyer in Q1 2018 was RA Capital Management, an estimated $31.6M added.
- The largest TG Therapeutics seller in Q1 2018 was Bridger Management, an estimated $25.8M sold.
Based on aggregated 13F filings for Q1 2018.